Exploring the Overlooked Growth Potential of Axsome Therapeutics, CRISPR Therapeutics, and Pfizer
Axsome Therapeutics: Unlocking Unrealized Growth
Prosper Junior Bakiny (Axsome Therapeutics): It's not easy to value relatively small, unprofitable biotechs with few products. However, Axsome Therapeutics boasts a rich, late-stage pipeline that could revolutionize its product lineup in the near future.
- Auvelity, one of Axsome Therapeutics' approved products, successfully passed a critical late-stage trial for treating Alzheimer's disease agitation.
- With a deep pipeline, Axsome Therapeutics may introduce up to five new products by the end of next year, offering substantial upside potential.
CRISPR Therapeutics: Riding the Gene-Therapy Wave
David Jagielski (CRISPR Therapeutics): With a high-growth potential gene-therapy market, CRISPR Therapeutics, priced attractively, holds the key to significant long-term growth.
- With the approved Casgevy gene-therapy treatment, CRISPR has a valuable asset poised for expansion.
- Further therapies in CRISPR's pipeline could drive substantial growth, reinforcing its financial stability.
Pfizer: Navigating Through Challenges
Keith Speights (Pfizer): Despite current challenges, Pfizer's promising growth strategies project solid revenue increases that might overshadow existing revenue losses.
- With new product launches and strategic acquisitions, Pfizer aims for substantial revenue gains and a promising CAGR between 2025 and 2030.
- Investors can leverage Pfizer's favorable valuation, growth potential, and high dividend yield for attractive total returns.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.